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Clinical PerspectiveWhat Is New?This is the largest study to investigate the incidence and outcomes of venous thromboembolism (VTE) in patients undergoing coronary artery bypass grafting (CABG).The incidence of VTE was low, but it was associated with increased morbidity and mortality, length of stay, and hospital costs in patients undergoing CABG.What Are the Clinical Implications?Our results urge clinicians to acknowledge that while perioperative VTE after CABG is rare, it is associated with significant morbidity and mortality. Appropriately selected patients may benefit from VTE prophylaxis.However, further work is needed to identify optimal practices for VTE prophylaxis in patients undergoing cardiac surgeries, including the choice of pharmacologic agent for pharmacological prophylaxis.

Introduction {#jah34357-sec-0008}
============

Venous thromboembolism (VTE) is a feared complication in patients undergoing surgical procedures and is associated with significant morbidity, mortality, and hospital costs.[1](#jah34357-bib-0001){ref-type="ref"}, [2](#jah34357-bib-0002){ref-type="ref"}, [3](#jah34357-bib-0003){ref-type="ref"} As a result, pharmacological prophylaxis against VTE is strongly recommended in the perioperative period for most surgical patients, and is a benchmark used to evaluate quality of care.[4](#jah34357-bib-0004){ref-type="ref"}, [5](#jah34357-bib-0005){ref-type="ref"}

However, for patients undergoing cardiac surgeries, including coronary artery bypass grafting (CABG), VTE prophylaxis is controversial. The incidence of perioperative VTE in CABG patients reported in the literature is low (≈1%).[6](#jah34357-bib-0006){ref-type="ref"}, [7](#jah34357-bib-0007){ref-type="ref"}, [8](#jah34357-bib-0008){ref-type="ref"} Unfortunately, a majority of the current evidence regarding the incidence and outcomes of VTE, and optimal strategies for VTE prophylaxis in patients undergoing CABG, is from studies with limited sample sizes, and is of moderate‐to‐low quality as acknowledged by guidelines.[9](#jah34357-bib-0009){ref-type="ref"}, [10](#jah34357-bib-0010){ref-type="ref"} Moreover, current evidence regarding benefit of prophylaxis versus bleeding complications is inconclusive.[11](#jah34357-bib-0011){ref-type="ref"}

Given the volume of patients undergoing CABG, and the significant adverse outcomes associated with perioperative VTE, we believe this issue needs further attention, and that a more robust understanding of the impact of VTE in the perioperative CABG period may help guide clinical management. In this study, we used a large national inpatient database to investigate the incidence and outcomes of perioperative VTE in patients undergoing CABG.

Methods {#jah34357-sec-0009}
=======

Data Source {#jah34357-sec-0010}
-----------

The data that support the findings of this study are available upon reasonable request. We obtained data from the 2013 to 2014 National Inpatient Sample (NIS) for this analysis. The NIS is the largest all‐payer inpatient database in the United States. With about 8 million records per year, it includes a sample of \>94% of discharges from all US hospitals, excluding federal facilities, and long‐term acute care and rehabilitation facilities.[12](#jah34357-bib-0012){ref-type="ref"} Discharge weights are provided to allow for production of national estimates. Given the de‐identified nature of NIS data, our study was considered exempt from our institution\'s Institutional Review Board. All analyses in our study are weighted using provided discharge weights unless stated otherwise.

Study Design {#jah34357-sec-0011}
------------

We used the *International Classification of Diseases, Ninth Revision, Clinical Modification* (*ICD‐9‐CM*) codes to identify all patients ≥18 years of age who underwent CABG during the study period (n=401 075). We also identified patients undergoing OPCAB (off‐pump coronary artery bypass grafting) using relevant *ICD‐9‐CM* codes for cardiopulmonary bypass support during surgery. We excluded hospitalizations with concomitant valvular procedures (n=69 125). Patients with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) were identified using their respective *ICD‐9‐CM* codes (see Tables [S1 through S3](#jah34357-sup-0001){ref-type="supplementary-material"} for list of *ICD‐9‐CM* codes used in this study). We excluded patients with a diagnosis of thromboembolism of superficial veins.

Patients were divided into 2 groups: those with or without VTE. For baseline characteristics, we used patient‐level characteristics such as age, sex, race, insurance status, and relevant comorbidities---history of prior VTE, alcohol abuse, malignancy (solid tumor and metastatic), anemias, heart failure, chronic pulmonary disease, coagulopathy, depression, diabetes mellitus, hypertension, liver disease, fluid and electrolyte disorders, neurological disorders, obesity, peripheral vascular disorders, chronic renal failure, valvular disease, smoking, and dyslipidemia. These comorbidities were identified using their respective *ICD‐9‐CM* codes (Table [S2](#jah34357-sup-0001){ref-type="supplementary-material"}). Hospital‐level characteristics included hospital bed size, location and teaching status, and region.

Outcomes {#jah34357-sec-0012}
--------

Our primary outcome of interest was all‐cause in‐hospital mortality. Secondary outcomes were incidence of acute kidney injury (AKI), AKI requiring dialysis (AKI‐D), stroke, acute respiratory failure, bleeding, hospital costs, and length of stay. Complications were identified using their respective *ICD‐9‐CM* codes (Table [S3](#jah34357-sup-0001){ref-type="supplementary-material"}).

Statistical Analysis {#jah34357-sec-0013}
--------------------

All statistical analyses were conducted using survey‐specific techniques accounting for the stratified and multilevel nature of the data.[13](#jah34357-bib-0013){ref-type="ref"} Categorical data are provided as counts and percentages, and continuous data are provided as means with standard deviations or standard errors. Cost of stay was calculated by multiplying the total charges for stay by the provided cost‐to‐charge ratios. Because length of stay and cost were non‐normally distributed, they were log‐transformed for all analyses, and then back‐transformed for reporting. Costs were inflation‐adjusted for 2018 using Consumer Price Index data provided by the US Department of Labor.

All covariates had complete information except primary expected payer (0.2% missing) and race (6.5% missing). For primary expected payer, the missing values were replaced with the dominant category. For race, the missing value was treated as a separate category in regression models. This approach has been used by prior studies utilizing the NIS.[14](#jah34357-bib-0014){ref-type="ref"}, [15](#jah34357-bib-0015){ref-type="ref"} Categorical variables were compared with the Pearson χ^2^ test, while all continuous variables were compared with the Student *t* test. Complex‐samples logistic or linear regression models adjusting for demographics, comorbidities, and hospital characteristics were used to compare in‐hospital outcomes. In an additional analysis, we also studied outcomes among patients with PE (with or without DVT), and patients with DVT only (without PE). Finally, we also assessed the influence of OPCAB on incidence of VTE, and on in‐hospital mortality.

Unadjusted and adjusted odds ratios (aOR) are presented with 95% CIs. Statistical significance for *P* values was set at \<0.05. All statistical analyses were done using the Statistical Package for Social Sciences version 25 (SPSS; IBM, Armonk, NY).

Results {#jah34357-sec-0014}
=======

During the study period, there were 331 950 weighted hospitalizations, of which 69 225 (20.9%) were OPCAB. Of the overall cohort, 1.3% (n=4205) had a concomitant diagnosis of VTE (0.4% \[n=1205\] with PE and 0.9% \[n=2940\] with only DVT \[without PE\]).

Compared with patients without VTE, patients with VTE were slightly older (mean age 67.2±10.4 years versus 65.2±10.4 years, *P*\<0.001), more likely to have a history of prior VTE (4.5% versus 1.8%, *P*\<0.001), heart failure (6.9% versus 1.0%, *P*\<0.001), coagulopathy (32.0% versus 17.8%, *P*\<0.001), and renal failure (23.3% versus 15.6%, *P*\<0.001). Baseline characteristics of the 2 groups are displayed in Table [1](#jah34357-tbl-0001){ref-type="table"}.

###### 

Baseline Characteristics of Study Population

  Characteristic                              No VTE (n=327 745)   VTE (n=4205)   *P* Value
  ------------------------------------------- -------------------- -------------- -----------
  Age, y                                      65.2±10.4            67.2±10.4      \<0.001
  Female                                      82 660 (25.2%)       1280 (30.4%)   \<0.001
  Race                                                                            
  White                                       240 775 (73.5%)      2960 (70.4%)   0.05
  Black                                       21 455 (6.5%)        440 (10.5%)    \<0.001
  Hispanic                                    22 745 (6.9%)        245 (5.8%)     0.21
  Other                                       21 605 (6.6%)        265 (6.3%)     0.74
  Missing                                     21 165 (6.5%)        295 (7.0%)     0.56
  Insurance                                                                       
  Medicare                                    184 800 (56.4%)      2720 (64.7%)   \<0.001
  Medicaid                                    22 875 (7.0%)        340 (8.1%)     0.22
  Private                                     105 060 (32.1%)      935 (22.2%)    \<0.001
  Self/uninsured                              15 010 (4.6%)        210 (5.0%)     0.56
  OPCAB                                       68 245 (20.8)        980 (23.3%)    0.09
  Comorbidities                                                                   
  Prior VTE                                   5840 (1.8%)          190 (4.5%)     \<0.001
  Alcohol abuse                               11 660 (3.6%)        210 (5.0%)     \<0.001
  Deficiency anemias                          54 985 (17.7%)       880 (20.9%)    \<0.001
  Chronic blood loss anemia                   3760 (1.1%)          50 (1.2%)      0.80
  Heart failure                               3145 (1.0%)          290 (6.9%)     \<0.001
  Chronic pulmonary disease                   72 305 (22.1%)       1145 (27.2%)   \<0.001
  Coagulopathy                                58 460 (17.8%)       1345 (32.0%)   \<0.001
  Depression                                  25 225 (7.7%)        310 (7.4%)     0.43
  Diabetes mellitus (without complications)   119 605 (36.5%)      1335 (31.7%)   \<0.001
  Diabetes mellitus (with complications)      31 200 (9.5%)        490 (11.7%)    0.04
  Hypertension                                266 290 (81.2%)      3025 (71.9%)   \<0.001
  Hypothyroidism                              33 810 (10.3%)       410 (9.8%)     0.23
  Liver disease                               5510 (1.7%)          85 (2.0%)      0.09
  Fluid and electrolyte disorders             104 885 (32.0%)      2230 (53.0%)   \<0.001
  Other neurological disorders                12 870 (3.9%)        230 (5.5%)     \<0.001
  Obesity                                     80 920 (24.7%)       1160 (27.6%)   \<0.001
  Peripheral vascular disorders               49 155 (15.0%)       940 (22.4%)    \<0.001
  Renal failure                               51 275 (15.6%)       980 (23.3%)    \<0.001
  Solid tumor (without metastasis)            3230 (1.0%)          15 (0.4%)      \<0.001
  Metastatic cancer                           545 (0.2%)           15 (0.4%)      0.003
  Valvular disease                            1075 (0.3%)          115 (2.7%)     \<0.001
  Smoking                                     68 190 (20.8%)       700 (16.6%)    \<0.001
  Dyslipidemia                                251 245 (76.7%)      2555 (60.8%)   \<0.001
  Bed size of hospital                                                            
  Small                                       29 295 (8.9%)        40 (5.7%)      \<0.001
  Medium                                      77 975 (23.8%)       885 (21.0%)    \<0.001
  Large                                       220 475 (67.3%)      3080 (73.2%)   \<0.001
  Hospital location and teaching status                                           
  Rural                                       11 625 (3.5%)        105 (2.2%)     \<0.001
  Urban nonteaching                           90 620 (27.6%)       1030 (24.5%)   \<0.001
  Urban teaching                              225 500 (68.8%)      3070 (73.0%)   \<0.001
  Region                                                                          
  Northeast                                   52 355 (16.0%)       585 (13.9%)    \<0.001
  Midwest                                     77 065 (23.5%)       975 (23.2%)    0.62
  South                                       145 095 (44.3%)      2035 (48.4%)   \<0.001
  West                                        53 230 (16.2%)       610 (14.5%)    0.002

Variables are mean±SD or n (%). OPCAB indicates off‐pump coronary artery bypass grafting; VTE, venous thromboembolism.

Independent predictors of VTE included the following: coagulopathy (aOR 1.71 \[95% CI 1.46--2.01\]; *P*\<0.001), history of prior VTE (aOR 2.52 \[95% CI 1.75--3.64\]; *P*\<0.001), heart failure (aOR 3.39 \[95% CI 2.33--4.93\]; *P*\<0.001), obesity (aOR 1.33 \[95% CI 1.12--1.57\]; *P*=0.001), and chronic pulmonary disease (aOR 1.21 \[95% CI 1.02--1.43\]; *P*=0.03). Off‐pump CABG was not an independent predictor of VTE (aOR 1.11 \[95% CI 0.95--1.31\], *P*=0.23) (Table [2](#jah34357-tbl-0002){ref-type="table"}).

###### 

Predictors of VTE During Hospitalization

  Risk Factor                 Adjusted OR \[95% CI\][a](#jah34357-note-0004){ref-type="fn"}   *P* Value
  --------------------------- --------------------------------------------------------------- -----------
  Coagulopathy                1.71 \[1.46--2.01\]                                             \<0.001
  Prior VTE                   2.52 \[1.75--3.64\]                                             \<0.001
  Heart failure               3.39 \[2.33--4.93\]                                             \<0.001
  Obesity                     1.33 \[1.12--1.57\]                                             0.001
  Age                         1.01 \[1.001--1.020\]                                           0.02
  Chronic pulmonary disease   1.21 \[1.02--1.43\]                                             0.03
  OPCAB                       1.11 \[0.95--1.31\]                                             0.23

OPCAB indicates off‐pump coronary artery bypass grafting; OR, odds ratio; VTE, venous thromboembolism.

Adjusted for age, race, sex, insurance status, hospital characteristics, and all comorbidities listed in Table [1](#jah34357-tbl-0001){ref-type="table"}.

Venous thromboembolism was associated with increased incidence of in‐hospital mortality (6.8% versus 1.7%; aOR 1.92 \[95% CI 1.40--2.65\]; *P*\<0.001), AKI (39.4% versus 16.3%; aOR 2.25 \[95% CI 1.88--2.69\]; *P*\<0.001), AKI‐D (3.9% versus 1.2%; aOR 1.66 \[95% CI 1.07--2.55\]; *P*=0.02), acute respiratory failure (45.1% versus 17.0%; aOR 2.71 \[95% CI 2.33--3.15\]; *P*\<0.001), stroke (6.7% versus 1.8%; aOR 2.52 \[95% CI 1.83--3.48\]; *P*\<0.001), and bleeding (18.2% versus 6.5%; aOR 2.22 \[95% CI 1.85--2.67\]; *P*\<0.001). VTE was also associated with higher cost (mean±SE \$81 995±\$923 versus \$48 909±\$55) and longer length of stay (mean±SE 17.06±0.16 days versus 8.52±0.01 days) (Table [3](#jah34357-tbl-0003){ref-type="table"}). Our findings were similar for patients with PE or DVT‐only (Table [S4](#jah34357-sup-0001){ref-type="supplementary-material"}).

###### 

In‐Hospital Outcomes in Patients Undergoing CABG With and Without VTE

  Outcome                                                                                                       No VTE      VTE                   *P* Value
  ------------------------------------------------------------------------------------------------------------- ----------- --------------------- -----------
  In‐hospital mortality                                                                                                                           
  Incidence, %                                                                                                  1.7         6.8                   
  Unadjusted OR \[95% CI\]                                                                                      Ref         4.14 \[3.14--5.45\]   \<0.001
  Adjusted OR \[95% CI\][a](#jah34357-note-0006){ref-type="fn"}                                                 Ref         1.92 \[1.40--2.65\]   \<0.001
  AKI                                                                                                                                             
  Incidence, %                                                                                                  16.3        39.4                  ···
  Unadjusted OR \[95% CI\]                                                                                      Ref         3.34 \[2.90--3.85\]   \<0.001
  Adjusted OR \[95% CI\][a](#jah34357-note-0006){ref-type="fn"}                                                 Ref         2.25 \[1.88--2.69\]   \<0.001
  AKI‐D                                                                                                                                           
  Incidence, %                                                                                                  1.2         3.9                   ···
  Unadjusted OR \[95% CI\]                                                                                      Ref         3.48 \[2.41--5.01\]   \<0.001
  Adjusted OR \[95% CI\][a](#jah34357-note-0006){ref-type="fn"}                                                 Ref         1.66 \[1.07--2.55\]   0.02
  Acute respiratory failure                                                                                                                       
  Incidence, %                                                                                                  17.0        45.1                  ···
  Unadjusted OR \[95% CI\]                                                                                      Ref         4.00 \[3.49--4.60\]   \<0.001
  Adjusted OR \[95% CI\][a](#jah34357-note-0006){ref-type="fn"}                                                 Ref         2.71 \[2.33--3.15\]   \<0.001
  Stroke                                                                                                                                          
  Incidence, %                                                                                                  1.8         6.7                   ···
  Unadjusted OR \[95% CI\]                                                                                      Ref         3.96 \[2.98--5.26\]   \<0.001
  Adjusted OR \[95% CI\][a](#jah34357-note-0006){ref-type="fn"}                                                 Ref         2.52 \[1.83--3.48\]   \<0.001
  Bleeding                                                                                                                                        
  Incidence, %                                                                                                  6.5         18.2                  ···
  Unadjusted OR \[95% CI\]                                                                                      Ref         3.21 \[2.69--3.82\]   \<0.001
  Adjusted OR \[95% CI\][a](#jah34357-note-0006){ref-type="fn"}                                                 Ref         2.22 \[1.85--2.67\]   \<0.001
  Length of stay                                                                                                                                  
  Days±SE                                                                                                       8.52±0.01   17.06±0.16            ···
  Unadjusted parameter estimate[b](#jah34357-note-0007){ref-type="fn"}                                          Ref         2.00 \[1.92--2.09\]   \<0.001
  Adjusted parameter estimate[a](#jah34357-note-0006){ref-type="fn"}, [b](#jah34357-note-0007){ref-type="fn"}   Ref         1.69 \[1.64--1.76\]   \<0.001
  Average hospital costs                                                                                                                          
  Mean±SE, \$                                                                                                   48 909±55   81 995±923            ···
  Unadjusted parameter estimate[b](#jah34357-note-0007){ref-type="fn"}                                          Ref         1.68 \[1.59--1.77\]   \<0.001
  Adjusted parameter estimate[a](#jah34357-note-0006){ref-type="fn"}, [b](#jah34357-note-0007){ref-type="fn"}   Ref         1.46 \[1.39--1.53\]   \<0.001

AKI indicates acute kidney injury; AKI‐D, AKI requiring dialysis; CABG, coronary artery bypass grafting; OR, odds ratio; VTE, venous thromboembolism.

Adjusted for age, race, sex, insurance status, hospital characteristics, and all comorbidities listed in Table [1](#jah34357-tbl-0001){ref-type="table"}.

Parameter estimates represent the antilog of the β regression coefficients obtained from the log‐transformed regression models.

Off‐pump CABG was not associated with in‐hospital mortality in the overall cohort (aOR 1.16 \[1.00--1.34\], *P*=0.05) or in the VTE cohort (1.78 \[0.90--3.53\], *P*=0.08) (Table [S5](#jah34357-sup-0001){ref-type="supplementary-material"}). In an analysis excluding all OPCAB cases, VTE continued to be associated with increased in‐hospital mortality (5.9% versus 1.7%, aOR 1.87 \[1.29--2.71\]) (Table [S6](#jah34357-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah34357-sec-0015}
==========

Our study is the largest, nationally representative study to demonstrate that while VTE in patients undergoing CABG is infrequent, it is associated with higher in‐hospital mortality and complications, longer length of stay, and higher average hospital costs.

VTE is a feared perioperative complication, and is associated with significant morbidity, mortality, prolonged hospital stays, and increased costs.[1](#jah34357-bib-0001){ref-type="ref"}, [2](#jah34357-bib-0002){ref-type="ref"}, [3](#jah34357-bib-0003){ref-type="ref"} While use of both mechanical and pharmacologic VTE prophylaxis is standard practice in most patients undergoing noncardiac surgery,[4](#jah34357-bib-0004){ref-type="ref"}, [5](#jah34357-bib-0005){ref-type="ref"} pharmacologic VTE prophylaxis remains controversial for patients undergoing cardiac surgery, and protocols can differ considerably across institutions, even though patients undergoing cardiac surgeries have been found to be at increased risk of VTE compared with those undergoing general surgeries.[6](#jah34357-bib-0006){ref-type="ref"}, [16](#jah34357-bib-0016){ref-type="ref"}, [17](#jah34357-bib-0017){ref-type="ref"} Several reasons may explain the hesitance to use pharmacologic VTE prophylaxis in cardiac surgery patients. First, some believe that the incidence of perioperative VTE in cardiac surgery patients is relatively rare to be of clinical importance.[18](#jah34357-bib-0018){ref-type="ref"} There is a higher perceived risk of hemorrhagic complications such as pericardial effusions,[19](#jah34357-bib-0019){ref-type="ref"}, [20](#jah34357-bib-0020){ref-type="ref"}, [21](#jah34357-bib-0021){ref-type="ref"} and thus some clinicians prefer only mechanical prophylaxis alone over pharmacological agents. Some also believe that the generous amounts of intraoperative anticoagulation used during the procedure may persist in the perioperative period and offer protection.[18](#jah34357-bib-0018){ref-type="ref"}, [22](#jah34357-bib-0022){ref-type="ref"}

However, prior work has found that patients undergoing cardiac surgery may be prothrombotic as early as postoperative day 1 persisting up to day 30.[23](#jah34357-bib-0023){ref-type="ref"}, [24](#jah34357-bib-0024){ref-type="ref"}, [25](#jah34357-bib-0025){ref-type="ref"} There is also evidence suggesting that pharmacological prophylaxis in these patients may be protective without significantly increasing the risk of clinically significant bleeding.[26](#jah34357-bib-0026){ref-type="ref"} Fatal PE has been reported as being the cause of up to 20% of unexplained deaths after cardiac surgery,[27](#jah34357-bib-0027){ref-type="ref"}, [28](#jah34357-bib-0028){ref-type="ref"} with as many as 50% being undiagnosed before death. Therefore, some advocate for early postprocedural initiation of pharmacological prophylaxis in patients who are not actively bleeding or those with multiple risk factors for VTE.[9](#jah34357-bib-0009){ref-type="ref"}, [16](#jah34357-bib-0016){ref-type="ref"}

Unfortunately, the best strategy for prophylaxis (or choice of pharmacological agent) remains unclear, with current evidence limited to small observational studies or randomized controlled trials. This lack of consensus regarding optimal prophylactic strategies is evident in conflicting guidelines.[9](#jah34357-bib-0009){ref-type="ref"}, [10](#jah34357-bib-0010){ref-type="ref"}, [11](#jah34357-bib-0011){ref-type="ref"} The European Association for Cardiothoracic Surgery recommends pharmacologic prophylaxis from the first perioperative day,[9](#jah34357-bib-0009){ref-type="ref"} while the American College of Chest Physicians (ACCP) deems cardiac surgery patients to be at moderate risk for VTE but high risk for bleeding, and currently recommends mechanical over pharmacologic prophylaxis for patients undergoing cardiac surgery (Grade 2C) and the addition of pharmacological agents (Grade 2C) if patients have a prolonged hospital stay because of nonhemorrhagic surgical complications.[10](#jah34357-bib-0010){ref-type="ref"} Unfortunately, although mechanical prophylaxis alone is generally preferred, poor patient tolerance and compliance may reduce the efficacy of this method.

The incidence of perioperative VTE observed in our study is consistent with previous findings in patients undergoing CABG.[6](#jah34357-bib-0006){ref-type="ref"}, [7](#jah34357-bib-0007){ref-type="ref"}, [18](#jah34357-bib-0018){ref-type="ref"} However, this is likely an underestimate, since diagnosis of VTE post cardiac surgery can be challenging as the signs and symptoms associated with DVT and PE (such as tachycardia, chest pain, leg erythema, and edema) can also be attributable to surgery. Moreover, some patients may also have asymptomatic VTE that would be otherwise undiagnosed. Viana et al found rates of postoperative DVT and PE (diagnosed utilizing computed tomographic pulmonary angiography and lower extremity venous compressive ultrasound) to be as high as 20%, in their prospective, observational, single‐center study of 100 patients undergoing elective CABG.[29](#jah34357-bib-0029){ref-type="ref"}

Cardiac surgery patients often have several risk factors for perioperative VTE, and the risk factors associated with VTE in our study (Table [2](#jah34357-tbl-0002){ref-type="table"}) have been identified by others as well.[30](#jah34357-bib-0030){ref-type="ref"}, [31](#jah34357-bib-0031){ref-type="ref"} It has also been postulated that OPCAB may be associated with increased thromboembolism compared with on‐pump CABG.[25](#jah34357-bib-0025){ref-type="ref"} We found that OPCAB was not associated with increased incidence of VTE in our population, nor was it associated with increased in‐hospital mortality. Furthermore, VTE continued to be associated with increased mortality despite exclusion of OPCAB cases from our analysis (Table [S6](#jah34357-sup-0001){ref-type="supplementary-material"}), further suggesting that VTE has an effect on mortality independent of OPCAB.

Our results urge clinicians to acknowledge that while VTE may be rare after CABG, it is still a real threat and is associated with increased morbidity and mortality. We did note a higher incidence of bleeding in the VTE group, which may be because of the use of therapeutic anticoagulation after diagnosis. Unfortunately, it is difficult to identify with certainty which patients are at risk for bleeding. However, as prior work has shown, some patients may not be at increased risk of bleeding and may benefit from earlier initiation of pharmacologic prophylaxis. Our results highlight a need for large randomized control trials to evaluate optimal prophylactic practices in patients undergoing CABG.

There are several important limitations to our study. First, our results are reliant on accurate *ICD‐9‐CM* coding, and some cases of superficial vein thromboses may have been misclassified as DVT. We attempted to mitigate this by excluding codes for superficial vein thrombosis from the DVT group. Second, since the NIS does not contain information on the type of VTE prophylaxis used in patients, there may have been patients who received mechanical and/or pharmacologic VTE prophylaxis in our study. Hence, we were not able to ascertain the influence of prophylaxis strategy on incidence and outcomes of VTE, including bleeding. Third, we could not identify the method used to diagnose VTE (imaging, clinical symptoms, or both), because this information is not available in the NIS. Fourth, because the NIS does not contain information on the temporal relationship between CABG and incidence of VTE, it is possible that some patients may have had acute VTE before CABG during the same hospitalization, and we were not able to exclude these patients from our analysis. Moreover, because the NIS is an inpatient‐only database, it does not contain any information on VTE events that may have occurred after discharge. Lastly, given the retrospective observational nature of our study, and the lack of granular information in the NIS, we were only able to show an association of VTE with increased mortality, and were unable to identify whether any deaths were directly attributable to VTE.

Conclusions {#jah34357-sec-0016}
===========

In our study of \>330 000 CABG procedures, we found that while the incidence of perioperative VTE is low, it is associated with increased in‐hospital morbidity and mortality, prolonged length of stay, and increased hospital costs. Unlike most surgeries for which it is strongly recommended, perioperative VTE prophylaxis in cardiac surgery patients remains controversial, and large randomized controlled trials are needed to evaluate optimal prophylaxis strategies.
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